APLS Apellis Pharmaceuticals Inc

Simplify Asset Management Inc. has acquired a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), purchasing 106,888 shares valued at approximately $2.42 million during the third quarter. This move comes as Apellis Pharmaceuticals outperformed earnings expectations, reporting an EPS of $1.67 against an estimated $1.03 and revenues of $458.6 million, a 133% increase year-over-year. The company currently has an average "Hold" rating from analysts with a price target of $33.94, despite recent insider share sales.

This article analyzes momentum shifts for Apellis Pharmaceuticals Inc. (NASDAQ: APLS) using AI models, highlighting a mixed sentiment alignment and a mid-channel oscillation pattern. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis indicating varying support and resistance levels. The report also details an exceptional short setup targeting a 20.0% downside with minimal risk.

Highland Capital Management LLC has acquired a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), purchasing over 50,000 shares valued at approximately $1.135 million. This move comes despite recent insider selling by the CFO and General Counsel, totaling over $1.3 million. Apellis Pharmaceuticals recently surpassed quarterly earnings and revenue estimates, yet analysts maintain a consensus "Hold" rating on the stock with an average target price of $33.94.

This article presents mixed analyst opinions on two healthcare stocks: Apellis Pharmaceuticals (APLS) and Argenx Se (ARGX). While Apellis Pharmaceuticals received a "Hold" rating from Mizuho Securities, it holds a "Moderate Buy" consensus from analysts. Argenx Se maintains a "Strong Buy" consensus, with William Blair and J.P. Morgan both issuing "Buy" ratings and significant price targets.

Mizuho Securities analyst Graig Suvannavejh has maintained a "hold" rating for Apellis Pharmaceuticals (APLS.US). The analyst has a 49.8% success rate and an average return of 15.8% over the past year, according to TipRanks data. The rating is for informational purposes and not an investment recommendation.

Stifel Nicolaus lowered its price target for Apellis Pharmaceuticals (NASDAQ:APLS) from $55.00 to $48.00, while maintaining a "buy" rating, indicating a potential upside of 93.22%. Despite a strong Q3 earnings report where Apellis exceeded revenue and EPS estimates, insider selling has occurred, and other analysts have varying ratings, leading to a consensus "Hold" rating with an average target price of $33.94. The company develops therapeutic compounds for autoimmune and inflammatory diseases, with its stock currently trading around $24.84.